Cargando…

Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines

Sulfonylureas (SUs) are one of the commonly prescribed oral anti-hyperglycemic agents (AHA) in low- and middle-income countries (LMICs), either in combination with metformin therapy or alone. However, concern about cardiovascular safety has limited the use of SUs in the management of type 2 diabetes...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohan, Viswanathan, Saboo, Banshi, Khader, Jabbar, Modi, Kirtikumar D, Jindal, Sushil, Wangnoo, Subhash Kumar, Amarnath, Sugumaran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854230/
https://www.ncbi.nlm.nih.gov/pubmed/35185350
http://dx.doi.org/10.1177/11795514221074663
_version_ 1784653402567868416
author Mohan, Viswanathan
Saboo, Banshi
Khader, Jabbar
Modi, Kirtikumar D
Jindal, Sushil
Wangnoo, Subhash Kumar
Amarnath, Sugumaran
author_facet Mohan, Viswanathan
Saboo, Banshi
Khader, Jabbar
Modi, Kirtikumar D
Jindal, Sushil
Wangnoo, Subhash Kumar
Amarnath, Sugumaran
author_sort Mohan, Viswanathan
collection PubMed
description Sulfonylureas (SUs) are one of the commonly prescribed oral anti-hyperglycemic agents (AHA) in low- and middle-income countries (LMICs), either in combination with metformin therapy or alone. However, concern about cardiovascular safety has limited the use of SUs in the management of type 2 diabetes mellitus (T2DM). Additionally, lack of uniformity in the national and international guidelines regarding the positioning of SUs in the management of diabetes has also been reported. The objective of this review was to assess the various national and international guidelines on diabetes management and understand the recommendations specific to SUs in various scenarios. A total of 33 national and international guidelines on the management of T2DM published in English were evaluated. These guidelines have considered the latest evidence and suggest the use of certain second-generation SUs as second-line therapy or in combination with other AHAs in select population and specific scenarios. Identification of the appropriate population, classification based on underlying risk, thorough assessment of the comorbid conditions, and a step-wise approach for the selection of appropriate SUs is essential for the effective management of T2DM. Additionally, cost-to–benefit ratio should be considered, particularly in LMICs, and SUs could continue to play an important role in such settings.
format Online
Article
Text
id pubmed-8854230
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-88542302022-02-19 Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines Mohan, Viswanathan Saboo, Banshi Khader, Jabbar Modi, Kirtikumar D Jindal, Sushil Wangnoo, Subhash Kumar Amarnath, Sugumaran Clin Med Insights Endocrinol Diabetes Review Article Sulfonylureas (SUs) are one of the commonly prescribed oral anti-hyperglycemic agents (AHA) in low- and middle-income countries (LMICs), either in combination with metformin therapy or alone. However, concern about cardiovascular safety has limited the use of SUs in the management of type 2 diabetes mellitus (T2DM). Additionally, lack of uniformity in the national and international guidelines regarding the positioning of SUs in the management of diabetes has also been reported. The objective of this review was to assess the various national and international guidelines on diabetes management and understand the recommendations specific to SUs in various scenarios. A total of 33 national and international guidelines on the management of T2DM published in English were evaluated. These guidelines have considered the latest evidence and suggest the use of certain second-generation SUs as second-line therapy or in combination with other AHAs in select population and specific scenarios. Identification of the appropriate population, classification based on underlying risk, thorough assessment of the comorbid conditions, and a step-wise approach for the selection of appropriate SUs is essential for the effective management of T2DM. Additionally, cost-to–benefit ratio should be considered, particularly in LMICs, and SUs could continue to play an important role in such settings. SAGE Publications 2022-02-14 /pmc/articles/PMC8854230/ /pubmed/35185350 http://dx.doi.org/10.1177/11795514221074663 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review Article
Mohan, Viswanathan
Saboo, Banshi
Khader, Jabbar
Modi, Kirtikumar D
Jindal, Sushil
Wangnoo, Subhash Kumar
Amarnath, Sugumaran
Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines
title Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines
title_full Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines
title_fullStr Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines
title_full_unstemmed Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines
title_short Position of Sulfonylureas in the Current ERA: Review of National and International Guidelines
title_sort position of sulfonylureas in the current era: review of national and international guidelines
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854230/
https://www.ncbi.nlm.nih.gov/pubmed/35185350
http://dx.doi.org/10.1177/11795514221074663
work_keys_str_mv AT mohanviswanathan positionofsulfonylureasinthecurrenterareviewofnationalandinternationalguidelines
AT saboobanshi positionofsulfonylureasinthecurrenterareviewofnationalandinternationalguidelines
AT khaderjabbar positionofsulfonylureasinthecurrenterareviewofnationalandinternationalguidelines
AT modikirtikumard positionofsulfonylureasinthecurrenterareviewofnationalandinternationalguidelines
AT jindalsushil positionofsulfonylureasinthecurrenterareviewofnationalandinternationalguidelines
AT wangnoosubhashkumar positionofsulfonylureasinthecurrenterareviewofnationalandinternationalguidelines
AT amarnathsugumaran positionofsulfonylureasinthecurrenterareviewofnationalandinternationalguidelines